首页> 外文OA文献 >Resolution of Persistent Cystoid Macular Edema due to Central Retinal Vein Occlusion in a Vitrectomized Eye following Intravitreal Implant of Dexamethasone 0.7 mg
【2h】

Resolution of Persistent Cystoid Macular Edema due to Central Retinal Vein Occlusion in a Vitrectomized Eye following Intravitreal Implant of Dexamethasone 0.7 mg

机译:解决了在玻璃体腔内植入地塞米松0.7 mg后,视网膜中央静脉闭塞引起的永久性囊样黄斑水肿的问题

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We report the case of a 62-year-old woman with a history of vitreoretinal surgery for vitreous hemorrhage secondary to central retinal vein occlusion (CRVO). Because of the persistence of macular edema (ME), she received 2 intravitreal injections of bevacizumab 0.5 mg (Avastin®, Genentech/Roche) three months after vitrectomy, without functional or anatomical improvement. Six months after vitrectomy, she therefore received an intravitreal implant of dexamethasone 0.7 mg (Ozurdex®). An improvement in her best-corrected visual acuity and central macular thickness, as measured by optical coherence tomography, was detected 7 days after the injection, and complete resolution of the ME and retinal hemorrhages was observed 6 months after the injection. Dexamethasone intravitreal implant might be an effective treatment option in ME secondary to CRVO, also in vitrectomized eyes.
机译:我们报告了一例62岁的女性,因玻璃体视网膜手术继发视网膜中央静脉阻塞(CRVO)而发生玻璃体出血的病史。由于黄斑水肿(ME)的持续存在,她在玻璃体切除术后三个月接受了两次玻璃体内注射的贝伐单抗0.5 mg(Avastin®,Genentech / Roche)的玻璃体内注射,但功能或解剖结构均未改善。玻璃体切除术后六个月,因此她接受了0.7 mg地塞米松的玻璃体内植入(Ozurdex®)。注射后7天,通过光学相干断层扫描技术测得的她的最佳矫正视力和黄斑中央膜厚度得到了改善,注射后6个月观察到ME和视网膜出血的完全缓解。地塞米松玻璃体内植入物可能是继发于CRVO的ME的有效治疗选择,也适用于玻璃体切除的眼睛。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号